BioCentury
ARTICLE | Financial News

Eyetech raises Macugen sales guidance

June 23, 2005 1:34 AM UTC

EYET raised its 2005 sales guidance for Macugen pegaptanib to $175-$190 million from $135-$150 million. EYET said Macugen had exceeded initial expectations, and that retinal specialists are adopting it faster than expected. EYET and partner Pfizer (PFE) launched the pegylated anti-VEGF aptamer in January. Macugen is in Phase II trials to treat central retinal vein occlusion (CRVO), and the partners plan to start a Phase II/III trial for diabetic macular edema (DME) in the second half. ...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article